Proteins: Form, Function, and Pathology Adrian Poniatowski Studyaid Biochemistry Seminar March 2, 2019 Biochemical Origami the Structure of Proteins

Total Page:16

File Type:pdf, Size:1020Kb

Proteins: Form, Function, and Pathology Adrian Poniatowski Studyaid Biochemistry Seminar March 2, 2019 Biochemical Origami the Structure of Proteins Proteins: Form, Function, and Pathology Adrian Poniatowski StudyAid Biochemistry Seminar March 2, 2019 Biochemical Origami The Structure of Proteins • From primary to quaternary structure • Pathologies are caused by misfolded proteins which are destabilized by seemingly minor amino acid changes • Form strictly defines function in the protein world • Tertiary structure will often be most clinically significant Primary Structure • Sequence of AA in protein • Creates robust bond resistant to • Read from N- (amino) to C- enviro chgs & flexible for folding (carboxyl) terminal • Dehydration synthesis • Peptide bond: covalent bond • Determines all higher structures between -NH3 (amino) and – COOH (carboxyl) groups α Helix (1 PP chain) Secondary Structure β Sheet (2+ PP chains) • α helix most common (3.6 AA/turn) • Stabilized by H-bonds b/w carbonyl O’s and amide N’s • β sheets can be parallel or antiparallel to each other • β sheets always have R-hand twist & form core of globular proteins Tertiary Structure • Hydrophobic side chains in interior, hydrophilic outside • Disulfide bridges between sulfide cont side chains provide covalent bond that provide max stability • H-bonds, ionic bonds, hydrophobic interactions contribute to architecture • Domains = fxnal 3D protein units • Denaturation affects 3-ary & 2-ary structures Protein Modification Folding & Denaturation • Chaperone proteins (HSP’s) sometimes coordinate the folding process • Denaturation is irreversible in proteins folded by HSP’s Ubiquitination • Regulates intracellular degradation of protein • Addition of one or more ubiquitin molecules to protein localizes it to proteasome for digestion Review Question Damaged cytosolic proteins are labeled with (1) and then are degraded by a protein complex called (2): A. (1) ubiquitin (2) translocon B. (1) oligosaccharide (2) chaperone C. (1) acetyl group at specific Lys residues (2) lysosome D. (1) ubiquitin (2) proteasome E. (1) phospahte at specific Ser or Thr residues (2) chaperone Conformational Pathologies • Abnormal structure or degradation is responsible for many systemic diseases • Misfolding secondary to non-silent mutation in RNA transcript (Sickle Cell, Glu /chg/ -> Val /np/ sub @ position 6) • Not enough protein made (OI) • Degradation of mutated-fxnal or normal protein (CF, AD) • Non-enzymatic/prion degradation (CJD) Alzheimer’s Disease • Hallmark: senile plaques formed • Hyperphosphorylated from β-Amyloid protein tau proteins form • APP cut by γ- and β-secretase to neurofibrillary tangles form β-Amyloid, which clumps • Microtubule system into plaques collapse • Widespread intracell disruption Systemic Amyloidoses • The abnormal cleavage of other proteins can lead to β sheet deposits in multiple organs • AL amyloidosis caused by deposition of Ig light chains in brain, heart, kidney, etc. • AA amyloidisis caused by Amyloid A deposition in mult organs, assoc w/ Rheum Arthritis, IBD, prolonged infectiom • AD is brain-specific amyloidosis Prions • Contagious pathogens comprised of small, misfolded proteins that induce abnormal folding of normal proteins • Aggregates of misfolded proteins are difficult to degrade and result in apoptosis and neuronal loss • Resistant to heat stress Prion Diseases Creutzfeldt-Jakob Disease • Spongiform encephalopathy • Rapidly progressive dementia Can be also inherited and • Ataxia & ultimately death acquired. Kuru secondary to ingestion of prion- • Irreversible & incurable infected tissue. • Caused by accumulation of PrP Review Question A pharmaceutical researcher develops a therapy to treat a protein misfolding disorder. Specifically, a mutation in this disorder leads to abnormal protein folding and subsequent intracellular degradation of the protein before it can reach the cell membrane. With the new drug therapy, a drug corrects the processing and trafficking of the protein, enabling it to reach the cell surface membrane. This therapy is most likely to be helpful in which of the following conditions? • A. Alzheimer disease • B. Creutzfeldt-Jakob disease • C. Cystic fibrosis • D. Phenylketonuria • E. Sickle cell anemia • Cystic fibrosis is caused by ΔF508 mutations in the cystic fibrosis transmembrane regulator (CFTR) protein • This deletion causes abnormal protein folding and failure of glycosylation. • The CFTR protein is then targeted for degradation by the proteasome before reaching the cell surface, causing an almost complete absence from the apical membrane of exocrine ductal epithelial cells. Connective Tissue Proteins Elastin Collagen • Triple helix • Has 3.3 residues per turn • Composed primarily of small non- polar AA’s • Every 3rd AA is a Gly • Rich in Pro and Lys • Motif: Gly-Pro-X or Gly-Hyp-X • Desmosine interchain crosslinks Collagen Synthesis • Synthesis: translation, usu Gly-X-Y (X,Y are typically Pro or Lys) • Hydroxylation: requires Vit C -> scurvy • Glycosylation: formation of triple helix. Problem here -> osteogenesis imperf • Exocytosis and extracell processing • Proteolysis: procollagen to tropocollagen (insoluble) • Cross-linking: CL’s lysine-hydroxylysine (by Cu-cont lysyl oxidase). Problem w/ cross-linking -> Ehlers-Danlos Diseases of Collagen Synthesis Osteogensis Imperfecta Ehlers-Danlos Syndrome Scurvy • • Spontaneous fractures • Joint Hypermobility Bleeding gums, bruises • Vitamin C is a necessary • Bone & tooth malform • Hyperextensible, fragile cofactor for the hydroxylation of proline and • Blue sclerae skin lysine residues in collagen. • Mutation in Type I • Mutation in Type V • Vitamin C deficiency results in decreased strength of collagen, insufficient collagen (Type III for collagen fibers and causes synthesis vascular disease) scurvy. Review Question The length of PCR products may be determined based on: A. The binding of a fluorescent dye B. UV light absorption C. Hybridization with specific probes D. Their migration in gel electrophoresis as compared to standards E. Melting temperature • Comparison of normal and mutant forms of gene PCR Method & Application • Prenatal Dx of inborn errors (e.g. cystic fibrosis) • Bacterial & viral microbio Dx • Forensic analysis and low- abundance DNA sample analysis Review Question Molecular biology techniques are used for the identification of individuals (genetic profiling in forensic medicine, clarifying paternity, etc). Nowadays, the most commonly used method is based on: A. Sequencing of specific genes B. Analysis of the number of short tandem repeats (STR) using PCR C. Electrophoretic separation of the total DNA isolated from cells D. Analysis of the number of repeats within telomeres E. Whole genome sequencing STRs and Forensic Medicine Who is going to prison? Who is going free? Source: Khan Academy Review Question The two most widely used methods of replication of any specific DNA sequence chosen by the experimentalist are molecular cloning and PCR. The fundamental difference between them is: A. Molecular cloning involves replication of the DNA within a living cell, while PCR replicates DNA in the test tube, free of living cells B. All answers are correct C. Molecular cloning generally uses DNA sequences from two different organisms, while PCR amplifies by copying an existing sequence D. Molecular cloning involves formation of recombinant DNA while PCR amplifies by copying an existing sequence E. Two answers are correct.
Recommended publications
  • Collagen and Elastin Fibres
    J Clin Pathol: first published as 10.1136/jcp.s3-12.1.49 on 1 January 1978. Downloaded from J. clin. Path., 31, Suppl. (Roy. Coll. Path.), 12, 49-58 Collagen and elastin fibres A. J. BAILEY From the Agricultural Research Council, Meat Research Institute, Langford, Bristol Although an understanding of the intracellular native collagen was generated from type I pro- biosynthesis of both collagen and elastin is of collagen. Whether this means that the two pro- considerable importance it is the subsequent extra- collagens are converted by different enzyme systems cellular changes involving fibrogenesis and cross- and the type III enzyme was deficient in these linking that ensure that these proteins ultimately fibroblast cultures, or that the processing of pro become the major supporting tissues of the body. type III is extremely slow, is not known. The latter This paper summarises the formation and stability proposal is consistent with the higher proportion of collagen and elastin fibres. of soluble pro type III extractable from tissue (Lenaers and Lapiere, 1975; Timpl et al., 1975). Collagen Basement membrane collagens, on the other hand, do not form fibres and this property may be The non-helical regions at the ends of the triple due to the retention of the non-helical extension helix of procollagen probably provide a number of peptides (Kefalides, 1973). In-vivo biosynthetic different intracellular functions-that is, initiating studies showing the absence of any extension peptide rapid formation of the triple helix; inhibiting intra- removal support this (Minor et al., 1976), but other cellular fibrillogenesis; and facilitating transmem- workers have reported that there is some cleavage brane movement.
    [Show full text]
  • Synthetic Polynucleotides Synthetische Polynukleotide Polynucleotides Synthetiques
    Europäisches Patentamt *EP000960192B1* (19) European Patent Office Office européen des brevets (11) EP 0 960 192 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C12N 9/02, C12N 15/53, of the grant of the patent: A61K 38/43, C12N 9/06 09.11.2005 Bulletin 2005/45 (86) International application number: (21) Application number: 97933592.4 PCT/AU1997/000505 (22) Date of filing: 11.08.1997 (87) International publication number: WO 1998/006830 (19.02.1998 Gazette 1998/07) (54) SYNTHETIC POLYNUCLEOTIDES SYNTHETISCHE POLYNUKLEOTIDE POLYNUCLEOTIDES SYNTHETIQUES (84) Designated Contracting States: • SHARP P M ET AL: "The codon Adaptation AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC Index--a measure of directional synonymous NL PT SE codon usage bias, and its potential applications." NUCLEIC ACIDS RESEARCH. (30) Priority: 09.08.1996 AU PO156596 ENGLAND 11 FEB 1987, vol. 15, no. 3, 11 February 1987 (1987-02-11), pages 1281-1295, (43) Date of publication of application: XP001122356 ISSN: 0305-1048 01.12.1999 Bulletin 1999/48 • DATABASE SWISSPROT [Online] 1 December 1992 (1992-12-01) MARIANI T.J. ET AL.: (60) Divisional application: "Protein-lysine 6-oxidase precursor (EC 05000327.6 1.4.3.13) (Lysyl oxidase)." Database accession no. P28300 XP002229125 (73) Proprietor: THE UNIVERSITY OF SYDNEY • DATABASE EMBL [Online] EBI; 16 May 1992 Sydney, New South Wales 2006 (AU) (1992-05-16) MARIANI T.J. ET AL.: "Human lysyl oxidase (LOX) mRNA, complete cds." Database (72) Inventor: WEISS, Anthony, Steven accession no. M94054 XP002229126 Randwick, NSW 2031 (AU) • DATABASE EMBL [Online] EBI; 26 November 1993 (1993-11-26) HAMALAINEN E.R.
    [Show full text]
  • Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid
    (19) TZZ _ T (11) EP 2 862 581 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.04.2015 Bulletin 2015/17 A61K 47/48 (2006.01) C07K 5/06 (2006.01) C07K 5/08 (2006.01) C07C 309/15 (2006.01) (2006.01) (2006.01) (21) Application number: 14200552.9 C07D 207/16 C07D 209/20 C07D 217/24 (2006.01) C07D 233/64 (2006.01) (2006.01) (2006.01) (22) Date of filing: 12.10.2007 C07D 291/02 C07D 333/24 C12P 11/00 (2006.01) A61K 38/07 (2006.01) A61K 38/08 (2006.01) A61P 25/28 (2006.01) (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Hoffmann Eitle Patent- und Rechtsanwälte PartmbB (30) Priority: 12.10.2006 US 851039 P Arabellastraße 30 12.04.2007 US 911459 P 81925 München (DE) (62) Document number(s) of the earlier application(s) in Remarks: accordance with Art. 76 EPC: This application was filed on 30-12-2014 as a 07875176.5 / 2 089 417 divisional application to the application mentioned under INID code 62. (71) Applicant: BHI Limited Partnership Laval, QC H7V 4A7 (CA) (54) Methods, compounds, compositions and vehicles for delivering 3- amino-1-propanesulfonic acid (57) The invention relates to methods, compounds, that will yield or generate 3APS, either in vitro or in vivo.
    [Show full text]
  • Revised ST.26 – 26/Oct/2016 ANNEX I
    Revised ST.26 – 26/Oct/2016 ANNEX I ST.26 - ANNEX I CONTROLLED VOCABULARY Final Draft TABLE OF CONTENTS SECTION 1: LIST OF NUCLEOTIDES ................................................................................................................................. 2 SECTION 2: LIST OF MODIFIED NUCLEOTIDES .............................................................................................................. 2 SECTION 3: LIST OF AMINO ACIDS ................................................................................................................................... 4 SECTION 4: LIST OF MODIFIED AND UNUSUAL AMINO ACIDS ..................................................................................... 5 SECTION 5: FEATURE KEYS FOR NUCLEIC SEQUENCES ............................................................................................ 6 SECTION 6: QUALIFIERS FOR NUCLEIC SEQUENCES ................................................................................................ 21 SECTION 7: FEATURE KEYS FOR AMINO ACID SEQUENCES ..................................................................................... 40 SECTION 8: QUALIFIERS FOR AMINO ACID SEQUENCES ........................................................................................... 47 SECTION 9: GENETIC CODE TABLES ............................................................................................................................. 48 Revised ST.26 – 26/Oct/2016 ANNEX I SECTION 1: LIST OF NUCLEOTIDES The nucleotide base codes to be used in sequence
    [Show full text]
  • Program 1..154
    The 97th Annual Meeting of CSJ Program Chair: INOUE, Haruo(15:30~15:55) Room S1 1S1- 15 Medium and Long-Term Program Lecture Artificial Photosynthesis of Ammonia(RIES, Hokkaido Univ.)○MISAWA, Hiroaki (15:30~15:55) Fourth Building, Section B J11 Chair: INOUE, Haruo(15:55~16:20) 1S1- 16 Medium and Long-Term Program Lecture Mechanism of water-splitting by photosystem II using the energy of visible light(Grad. Sustainable and Functional Redox Chemistry Sch. Nat. Sci. Technol., Okayama Univ.)○SHEN, Jian-ren(15:55~ ) Thursday, March 16, AM 16:20 (9:30 ~9:35 ) Chair: TAMIAKI, Hitoshi(16:20~16:45) 1S1- 01 Special Program Lecture Opening Remarks(Sch. Mater. & 1S1- 17 Medium and Long-Term Program Lecture Excited State Chem. Tech., Tokyo Tech.)○INAGI, Shinsuke(09:30~09:35) Molecular Dynamics of Natural and Artificial Photosynthesis(Sch. Sci. Tech., Kwansei Gakuin Univ.)○HASHIMOTO, Hideki(16:20~16:45) Chair: ATOBE, Mahito(9:35 ~10:50) 1S1- 02 Special Program Lecture Polymer Redox Chemistry toward Chair: ISHITANI, Osamu(16:45~17:10) Functional Materials(Sch. Mater. & Chem. Tech., Tokyo Tech.)○INAGI, 1S1- 18 Medium and Long-Term Program Lecture Recent pro- Shinsuke(09:35~09:50) gress on artificial photosynthesis system based on semiconductor photocata- 1S1- 03 Special Program Lecture Organic Redox Chemistry Enables lysts(Grad. Sch. Eng., Kyoto Univ.)○ABE, Ryu(16:45~17:10) Automated Solution-Phase Synthesis of Oligosaccharides(Grad. Sch. Eng., Tottori Univ.)○NOKAMI, Toshiki(09:50~10:10) (17:10~17:20) 1S1- 04 Special Program Lecture Redox Regulation of Functional 1S1- 19 Medium and Long-Term Program Lecture Closing re- Dyes and Their Applications to Optoelectronic Devices(Fac.
    [Show full text]
  • Growth, Elastin Concentration, and Collagen Concentration of Perinatal Rat Lung: Effects of Dexamethasone
    003 1-3998/87/2 106-0603$02.00/0 PEDIATRIC RESEARCH Vol. 21, No. 6, 1987 Copyright O 1987 International Pediatric Research Foundation, Inc Printed in U.S. A. Growth, Elastin Concentration, and Collagen Concentration of Perinatal Rat Lung: Effects of Dexamethasone JEAN-CLAUDE SCHELLENBERG, GRAHAM C. LIGGINS, AND ALISTAIR W. STEWART Postgraduate School of Obstetrics and Gynaecology [J-C.S., G.C.L.] and Department of Community Health [A. W.S.], The University of Auckland, Auckland, New Zealand ABSTRACT. The ontogenesis of elastin and collagen ac- phological (8) or biochemical structural analysis is required. cumulation and growth of the lung were studied in Wistar Although elastin and collagen have been used as markers of rats from day 18 of gestation until day 30 postnatally. connective tissue structure of the lung in newborn and adolescent Dexamethasone phosphate 0.1 mg or normal saline solu- rats (9-12), no data are available on the fetal rat lung. The tion every 8 h for three doses was injected into pregnant present study reports the ontogenesis of collagen and elastin rats on day 17. The effects of treatment, age, and sex on accumulation in rat lung between day 18 of gestation and day lung wet weight, lung dry weight, body weight, DNA, 30 postpartum and investigates the effects of prenatal glucocor- protein and desmosine (estimated by radioimmunoassay), ticoid administration on growth and structural development of and hydroxyproline were determined in the offspring. Dex- the rat lung. A radioimmunoassay for the determination of amethasone inhibited lung growth and, to a lesser extent, desmosine, a specific cross-link amino acid of elastin (13) is body weight gain.
    [Show full text]
  • WO 2010/037397 Al
    (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 8 April 2010 (08.04.2010) WO 2010/037397 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/17 (2006.01) C07K 14/705 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/48 (2006.01) GOlN 33/50 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/DK2009/050257 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 October 2009 (01 .10.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every PA 2008 0 1381 1 October 2008 (01 .10.2008) DK kind of regional protection available): ARIPO (BW, GH, 61/101,898 1 October 2008 (01 .10.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): DAKO TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, DENMARK A/S [DK/DK]; Produktionsvej 42, DK-2600 ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Glostrup (DK).
    [Show full text]
  • Liberation of Desmosine and Isodesmosine As Amino Acids from Insoluble Elastin by Elastolytic Proteases
    Liberation of desmosine and isodesmosine as amino acids from insoluble elastin by elastolytic proteases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Umeda, Hideyuki, Masanori Aikawa, and Peter Libby. 2011. “Liberation of Desmosine and Isodesmosine as Amino Acids from Insoluble Elastin by Elastolytic Proteases.” Biochemical and Biophysical Research Communications 411, no. 2: 281–286. Published Version doi:10.1016/j.bbrc.2011.06.124 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32605695 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Biochem Biophys Res Commun. Author manuscript; available in PMC 2012 July 29. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Biochem Biophys Res Commun. 2011 July 29; 411(2): 281±286. doi:10.1016/j.bbrc.2011.06.124. Liberation of Desmosine and Isodesmosine as Amino Acids from Insoluble Elastin by Elastolytic Proteases Hideyuki Umeda, Ph.D., Masanori Aikawa, M.D., Ph.D., and Peter Libby, M.D. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA Abstract The development of atherosclerotic lesions and abdominal aortic aneurysms involves degradation and loss of extracellular matrix components, such as collagen and elastin. Releases of the elastin cross-links desmosine (DES) and isodesmosine (IDE) may reflect elastin degradation in cardiovascular diseases.
    [Show full text]
  • ST.25 Page: 3.25.1
    HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.1 STANDARD ST.25 STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN PATENT APPLICATIONS Revision adopted by the SCIT Standards and Documentation Working Group at its eleventh session on October 30, 2009 It is recommended that Offices apply the provisions of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” as set out in Annex C to the Administrative Instructions under the PCT, mutatis mutandis, to all patent applications other than the PCT international applications, noting that certain provisions specific to PCT procedures and requirements may not be applicable to patent applications other than PCT international applications(*). The text of that PCT Standard is reproduced on the following pages. (*) If, on July 1, 2009, the national law and practice applicable by an Office is not compatible with the provisions of paragraph 3(i) of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” requiring that a sequence listing which is contained in the international application as filed “shall be presented as a separate part of the description, be placed at the end of the application, preferably be entitled ‘Sequence Listing’, begin on a new page and have independent page numbering”, that Office may choose not to follow those provisions for as long as that incompatibility continues. en / 03-25-01 Date: December 2009 HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.2 ANNEX C STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN INTERNATIONAL PATENT APPLICATIONS UNDER THE PCT INTRODUCTION 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,999,716 B2 Gundlach Et Al
    US0089997 16B2 (12) United States Patent (10) Patent No.: US 8,999,716 B2 Gundlach et al. (45) Date of Patent: Apr. 7, 2015 (54) ARTIFICIAL MYCOLIC ACID MEMBRANES USPC ..................................... 977/712 714; 436/71 See application file for complete search history. (75) Inventors: Jens Gundlach, Seattle, WA (US); Ian M. Derrington, Seattle, WA (US); Kyle W. Langford, University Place, WA (56) References Cited (US) U.S. PATENT DOCUMENTS (73) Assignee: University of Washington, Seattle, WA 6,171,830 B1* 1/2001 Verschoor ..................... 435.134 (US) 6,406,880 B1 6/2002 Thornton 2002/0052412 A1* 5/2002 Verschoor et al. ............ 514/557 - r 2004, OO63200 A1 4/2004 Chaikof (*) Notice: sity is titly 2006/0008519 A1 1/2006 Davidsen et al. ............. 424/450 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/592,030 FOREIGN PATENT DOCUMENTS JP O7-248329 A 9, 1995 (22) Filed: Aug. 22, 2012 WO 2007041621 A2 4, 2007 (65) Prior Publication Data OTHER PUBLICATIONS US 2013/0146456A1 Jun. 13, 2013 Butler, T. Z. et al. “Single-molecule DNA detection with an engi Related U.S. Application Data neered MspA protein nanopore'. Proceedings of the National Acad .S. App emy of Science USA, vol. 105, No. 52, Dec. 30, 2008, p. 20647 (63) Continuation of application No. 2O652* PCT/US2011/025960, filed on Feb. 23, 2011. (Continued) (60) Provisional application No. 61/307,441, filed on Feb. fEEE application No. 61/375,707, Primary Examiner — J. Christopher Ball • 1- ws (74) Attorney, Agent, or Firm — Christensen O'Connor (51) Int. Cl.
    [Show full text]
  • Altered Glycosylation in Pancreatic Cancer: Development of New Tumor Markers and Therapeutic Strategies
    ALTERED GLYCOSYLATION IN PANCREATIC CANCER: DEVELOPMENT OF NEW TUMOR MARKERS AND THERAPEUTIC STRATEGIES Pedro Enrique Guerrero Barrado Per citar o enllaçar aquest document: Para citar o enlazar este documento: Use this url to cite or link to this publication: http://hdl.handle.net/10803/671007 ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996).
    [Show full text]
  • Studies on the Chemistry and Fine Structure of Elastic Fibers from Normal Adult Skin* David P
    Till:: JOURNAL Ot" I NVf~ST I GAT I VE DEilMATOLOCY Vo l. 59, No. 3 Copy ri ght © 1972 by The \Vill inms & \Vilkins Cu. Printed in U.S ..4.. STUDIES ON THE CHEMISTRY AND FINE STRUCTURE OF ELASTIC FIBERS FROM NORMAL ADULT SKIN* DAVID P. VARADI, M.D., F.R. C. P. (C) ABS TRACT Collagenase-prepared, purified elastic fibers from adult huma n skin consist of at least two morphologically distinct components, the unstained a morphous component, and inter­ nally-located, deeply staining microfibrils. Separation a nd isolation of the amorphous component was achieved by alka li preparation of the elastic fibers. E lectron micrographs of a lkali prepared fibers showed essentia lly a morphous componen t as most of the microfibrils had been solubilized. The a mino acid composition of the amorphous component was that of classical elastin. The microfibrillar component embedded deep wi thin the interstices of the fiber was sepa rated by, first, re movin g the a morphous component with elastase, a nd subse­ quently solubilizing, with dithioerythritol (DTE), the cystine-containing microfibrils con­ tained in the elastase-produced residue. The amino acid composition of this DTE-ex­ t racted microfibrilla r material was similar to that of the peripheral microfibrillar compo­ nent enzymatically removed from bovine fetal elastic fibers. Electron microscopi c moni ­ toring showed that only stained microfibrils remained after elastase digestion. A protein portion of the microfibrilla r component was not solubilized by the DTE and was presumed to contain a low concentrat ion of disulfide bonds. Studies on purified elastin (amorphous component) revealed that a lanine is concentrated around desmosine crosslinks and that the pyrollidines a re uniformly distributed a long t he elastin molecule thereby precluding a a-helix conformation.
    [Show full text]